Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) harboring BIM deletion polymorphism (BIM deletion) have poor responses to EGFR TKI. Mechanistically, the BIM deletion induces preferential splicing of the non‐functional exon 3‐containing isoform over th...

詳細記述

保存先:
書誌詳細
出版年:Cancer Sci
主要な著者: Takeuchi, Shinji, Hase, Tetsunari, Shimizu, Shinobu, Ando, Masahiko, Hata, Akito, Murakami, Haruyasu, Kawakami, Takahiro, Nagase, Katsuhiko, Yoshimura, Kenichi, Fujiwara, Tadami, Tanimoto, Azusa, Nishiyama, Akihiro, Arai, Sachiko, Fukuda, Koji, Katakami, Nobuyuki, Takahashi, Toshiaki, Hasegawa, Yoshinori, Ko, Tun Kiat, Ong, S. Tiong, Yano, Seiji
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7004511/
https://ncbi.nlm.nih.gov/pubmed/31782583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14260
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料